Stacy L. Moulder

7.6k total citations · 1 hit paper
141 papers, 3.9k citations indexed

About

Stacy L. Moulder is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Stacy L. Moulder has authored 141 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 116 papers in Oncology, 58 papers in Cancer Research and 46 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Stacy L. Moulder's work include HER2/EGFR in Cancer Research (45 papers), Cancer Treatment and Pharmacology (40 papers) and Breast Cancer Treatment Studies (34 papers). Stacy L. Moulder is often cited by papers focused on HER2/EGFR in Cancer Research (45 papers), Cancer Treatment and Pharmacology (40 papers) and Breast Cancer Treatment Studies (34 papers). Stacy L. Moulder collaborates with scholars based in United States, United Kingdom and Canada. Stacy L. Moulder's co-authors include Carlos L. Arteaga, F. Michael Yakes, Vicente Valero, Razelle Kurzrock, Roberto Bianco, Senthil K. Muthuswamy, Jean F. Simpson, Gabriel N. Hortobágyi, Jennifer K. Litton and Jennifer J. Wheler and has published in prestigious journals such as Journal of Clinical Oncology, Molecular and Cellular Biology and Cancer.

In The Last Decade

Stacy L. Moulder

134 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype

2017 417 citations W. Fraser Symmans, Vicente Valero et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stacy L. Moulder United States	32	2.5k	1.4k	1.3k	922	589	141	3.9k
Ludmila Prudkin United States	23	1.9k 0.8×	1.7k 1.2×	1.5k 1.2×	804 0.9×	522 0.9×	50	3.8k
Mothaffar F. Rimawi United States	31	3.0k 1.2×	1.5k 1.0×	1.3k 1.0×	995 1.1×	901 1.5×	116	4.4k
Dimitrios Zardavas Belgium	21	2.1k 0.8×	945 0.7×	1.3k 1.0×	854 0.9×	589 1.0×	69	3.3k
Otto Metzger United States	30	3.2k 1.3×	1.4k 1.0×	1.7k 1.3×	1.4k 1.5×	540 0.9×	117	4.8k
Mario Giuliano Italy	34	2.4k 1.0×	1.0k 0.7×	1.4k 1.1×	1.2k 1.3×	328 0.6×	109	3.8k
Vandana G. Abramson United States	34	2.7k 1.1×	1.4k 1.0×	1.2k 0.9×	1.3k 1.4×	1.2k 2.0×	119	4.9k
Alexey Manikhas Russia	23	3.1k 1.2×	880 0.6×	1.4k 1.1×	1.4k 1.5×	763 1.3×	89	3.9k
Florence Lerebours France	29	1.4k 0.6×	915 0.6×	1.2k 1.0×	692 0.8×	322 0.5×	97	2.6k
Shaheenah Dawood United Arab Emirates	32	3.4k 1.4×	989 0.7×	2.3k 1.8×	1.4k 1.6×	869 1.5×	109	5.1k
Bárbara Adamo Spain	25	1.8k 0.7×	1.7k 1.2×	1.4k 1.1×	1.0k 1.1×	248 0.4×	99	3.7k

Countries citing papers authored by Stacy L. Moulder

Since Specialization

Citations

This map shows the geographic impact of Stacy L. Moulder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stacy L. Moulder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stacy L. Moulder more than expected).

Fields of papers citing papers by Stacy L. Moulder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stacy L. Moulder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stacy L. Moulder. The network helps show where Stacy L. Moulder may publish in the future.

Co-authorship network of co-authors of Stacy L. Moulder

This figure shows the co-authorship network connecting the top 25 collaborators of Stacy L. Moulder. A scholar is included among the top collaborators of Stacy L. Moulder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stacy L. Moulder. Stacy L. Moulder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Damodaran, Senthil, Diane Liu, Jill L. Schwartz, et al.. (2023). Abstract P3-02-03: A phase Ib trial of bintrafusp alfa and eribulin in patients with metastatic triple negative breast cancer (TNBC). Cancer Research. 83(5_Supplement). P3–2. 2 indexed citations

Liu, Xuan, Zhongqi Ge, Fei Yang, et al.. (2022). Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers. npj Breast Cancer. 8(1). 64–64. 5 indexed citations

Candelaria, Rosalind P., Beatriz E. Adrada, Kenneth R. Hess, et al.. (2020). Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. European Journal of Radiology. 130. 109170–109170. 6 indexed citations

Yam, Clinton, Gaiane M. Rauch, Meghan Karuturi, et al.. (2020). A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Investigational New Drugs. 39(2). 509–515. 24 indexed citations

Huang, Xiao, Qingqing Ding, Hua Guo, et al.. (2020). Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma. Human Pathology. 108. 42–50. 25 indexed citations

Candelaria, Rosalind P., Beatriz E. Adrada, Wei Wei, et al.. (2019). Imaging features of triple-negative breast cancers according to androgen receptor status. European Journal of Radiology. 114. 167–174. 15 indexed citations

Clifton, Katherine, Angelica M. Gutierrez‐Barrera, Junsheng Ma, et al.. (2018). Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Research and Treatment. 170(1). 101–109. 18 indexed citations

Moulder, Stacy L., Erika Hamilton, Cristiano Ferrario, et al.. (2017). Progression-free survival (PFS) and site of first progression in HER2+ metastatic breast cancer (MBC) patients (pts) with (w) or without (w/o) brain metastases: A pooled analysis of tucatinib phase I studies. Annals of Oncology. 28. v85–v85. 2 indexed citations

Moulder, Stacy L., Jennifer K. Litton, EA Mittendorf, et al.. (2016). Improving outcomes in triple-negative breast cancer (TNBC) using molecular characterization and diagnostic imaging to identify and treat chemo-insensitive disease. Annals of Oncology. 27. vi67–vi67. 1 indexed citations

10.

Litton, Jennifer K., Marion E. Scoggins, Rashmi K. Murthy, et al.. (2016). A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation. Annals of Oncology. 27. vi46–vi46. 17 indexed citations

11.

Kato, Shumei, Stacy L. Moulder, Naoto T. Ueno, et al.. (2015). Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience. 2(6). 576–580. 36 indexed citations

12.

Ganesan, Prasanth, Stacy L. Moulder, J. Jack Lee, et al.. (2014). Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents. Molecular Cancer Therapeutics. 13(12). 3175–3184. 29 indexed citations

13.

Pusztai, Lajos, Stacy L. Moulder, Mehmet Altan, et al.. (2014). Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer. Clinical Cancer Research. 20(20). 5265–5271. 28 indexed citations

14.

Murthy, Rashmi K., Ankur Varma, Kenneth R. Hess, et al.. (2014). Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2‐positive metastatic breast cancer. Cancer. 120(13). 1932–1938. 33 indexed citations

15.

Falchook, Gerald S., Stacy L. Moulder, Aung Naing, et al.. (2014). A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Investigational New Drugs. 33(1). 177–186. 11 indexed citations

16.

Wheler, Jennifer J., Apostolia M. Tsimberidou, David S. Hong, et al.. (2012). Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience. Clinical Cancer Research. 18(10). 2922–2929. 77 indexed citations

17.

Hong, David S., Jennifer H. Choe, Aung Naing, et al.. (2012). A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Investigational New Drugs. 31(4). 918–926. 22 indexed citations

18.

Münster, Pamela N., Carolyn D. Britten, Monica Mita, et al.. (2007). First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors. Clinical Cancer Research. 13(4). 1238–1245. 24 indexed citations

19.

Sparano, Joseph A., Stacy L. Moulder, Aslamuzzaman Kazi, et al.. (2006). Targeted Inhibition of Farnesyltransferase in Locally Advanced Breast Cancer: A Phase I and II Trial of Tipifarnib Plus Dose-Dense Doxorubicin and Cyclophosphamide. Journal of Clinical Oncology. 24(19). 3013–3018. 54 indexed citations

20.

Arteaga, Carlos L., Stacy L. Moulder, & F. Michael Yakes. (2002). HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Seminars in Oncology. 29(3). 4–10. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact